Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Juventas CAR-T LBCL Launch Marks Second Indication
CAR-TJuventas Cell Therapy

Juventas CAR-T LBCL Launch Marks Second Indication

BMS Breyanzi MZL FDA Approval First CAR-T
BMSBristol-Myers Squibb

BMS Breyanzi MZL FDA Approval First CAR-T

Novo Nordisk semaglutide Alzheimer's biomarkers fail primary endpoint
Clinical trial resultsHot targets

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
Clinical trial approval / initiationFosun Kite Biotechnology

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Show More